METiS Technologies Secures RMB 400 Million Series D Financing as Sanofi Exits Chinese Market with PCSK9 Inhibitor Alirocumab
METiS TechBio
AI-Driven Drug Formulation Developer
Amino Observation - Original Production by the Innovative Drug Team
Author | Huang Kai
AI in the Life Sciences Field Gains Attention.
Recently, METiS TechBio announced the completion of its Series D financing. The total amount raised in this round was 400 million RMB, jointly led by the Beijing Medical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund. The funds will accelerate the advancement of several strategic priorities for METiS TechBio, including platform automation upgrades, progress in the self-developed product pipeline, deepening international strategic cooperation, and the recruitment of high-end talent.
Sanofi Strategic Adjustment.
Recently, according to media reports, several hospitals have recently received formal notice from Sanofi: the new lipid-lowering drug Alirocumab will stop its promotion in the Chinese market and gradually exit the Chinese market, with the issuance date shown as July 2025.
In the past day, what hot topics in the pharmaceutical markets at home and abroad are worth paying attention to? Let Amino take you to explore.
/ 01 /
Market Express
1) Sanofi's PCSK9 Monoclonal Antibody Withdraws from China
Recently, according to media reports, several hospitals have recently received formal notices from Sanofi: the new lipid-lowering drug Praluent (Alirocumab) will stop its promotion in the Chinese market and gradually exit the Chinese market, with the notification dated July 2025.
/ 02 /
Capital Information
1) METiS TechBio Completes D Round Financing of 400 Million Yuan
Recently, METiS TechBio announced the completion of its Series D financing. The total amount raised in this round was 400 million RMB, jointly led by the Beijing Medical and Health Industry Investment Fund and the Daxing District Industrial Investment Fund. The funds will accelerate the advancement of several strategic priorities for METiS TechBio, including platform automation upgrades, progress in the self-developed product pipeline, deepening international strategic cooperation, and the recruitment of top talent.
2) Biocytogen expects to be profitable in the first half of 2025
On August 4, Biocytogen announced that its revenue for the first half of 2025 is expected to be approximately RMB 616 million to RMB 626 million, compared to approximately RMB 410.5 million in the same period last year, representing a year-over-year increase of approximately 50.1% to 52.5%. The net profit for the first half of 2025, ending June 30, is expected to be approximately RMB 42.7 million to RMB 52.7 million, compared to a loss of approximately RMB 50.7 million in the same period last year, turning losses into profits year-over-year.
/ 03 /
Pharmaceutical News
1) Phase II Clinical Trial Results of METiS TechBio's CKBA Ointment for Vitiligo Achieve Expected Goals
On August 4, Taien Kang announced that the Phase II clinical trial of CKBA ointment for vitiligo has been completed. The results showed positive efficacy and good safety, achieving the expected goals and supporting the continuation of Phase III trials.
2) YunDing New Glory Nefukang Expansion Approved
On August 4, Everest Medicines announced that the supplemental application for the expansion of production of its drug Nefukang (Budesonide Enteric-Coated Capsules), the first and only fully approved treatment for IgA nephropathy in China, has been officially approved by the National Medical Products Administration of China.
PS: Welcome to scan the QR code below to add the WeChat ID of Amino Jun for communication.
